Home » Newsletters » BioWorld Science

BioWorld Science

April 3, 2012

View Archived Issues

Trials reveal efficacy of REGN-727 in treating hypercholesterolemia

Studies further delineate clinical efficacy of mipomersen

Detailed phase II data disclosed on solithromycin at ECCMID

Novel imidazopyridines identified as potential hepatitis C therapeutics

Exenatide shows potential as a cardioprotective agent

Novel acetyl-CoA carboxylase 2 inhibitors prepared at Boehringer Ingelheim

Spanish scientists patent new apoptosis-inducing agents

New histamine H3 receptor ligands disclosed by Suven Life Sciences

Novel protein kinase inhibitors patented by Suzhou Ascepion Pharmaceuticals

Encouraging data on multikinase inhibitor support clinical development

Shionogi-ViiV Healthcare reports initial data from phase III dolutegravir trial

Actelion's miglustat obtains approval in Japan

Treatment starts in first-in-human rVIIa-FP study

Actelion focuses on follow-up prostanoid DP2 receptor antagonist

Shire reports topline results from PREVENT2 trial

Novartis Nanobody candidate clear to enter phase I trial

Raptor Pharmaceutical submits NDA for RP-103

Alfresa Pharma files application in Japan for tetrabenazine

Synageva BioPharma and Mitsubishi Tanabe Pharma expand collaboration

Keryx Biopharmaceuticals reports topline data from X-PECT

PLx Pharma receives grant for research into treatment for heart defect in premature babies

FDA approves Levemir label update

PolyTherics and Spirogen to collaborate on novel ADCs for cancer

Minirinmelt tablets approved in Japan

Nektar commences dosing in phase I study of new short-acting opioid for acute pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.